OSVYRTI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OSVYRTI (OSVYRTI).
Osvyrti (ruxolitinib) is a Janus kinase (JAK) inhibitor, specifically inhibiting JAK1 and JAK2. It inhibits STAT phosphorylation and modulates hematopoiesis and immune function.
| Metabolism | Primarily metabolized by CYP3A4, with minor contribution from CYP2C9. |
| Excretion | Primarily renal excretion as unchanged drug (approximately 70%) and as inactive metabolites (approximately 20%); less than 10% is excreted in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is approximately 12 hours in healthy adults, providing once-daily dosing; may be prolonged in renal impairment (up to 24 hours in severe impairment). |
| Protein binding | Approximately 94% bound to serum albumin and alpha-1-acid glycoprotein; binding is independent of drug concentration. |
| Volume of Distribution | Volume of distribution is 0.8 L/kg, indicating moderate tissue distribution; higher Vd in elderly and patients with hepatic cirrhosis. |
| Bioavailability | Oral bioavailability is approximately 60% (range 50-70%) due to first-pass metabolism; food does not significantly affect absorption. |
| Onset of Action | Oral administration: therapeutic effect observed within 2-4 hours; peak clinical effect at 6-8 hours. |
| Duration of Action | Duration of action is approximately 24 hours for blood pressure reduction, allowing once-daily dosing; sustained effect over 24 hours confirmed by ambulatory blood pressure monitoring. |
Adults: 50 mg orally once daily with or without food.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to severe renal impairment, including end-stage renal disease not on dialysis. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of data. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years. |
| Geriatric use | No specific dose adjustment required; use with caution due to age-related physiological changes and potential comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OSVYRTI (OSVYRTI).
| Breastfeeding | Osvyrti (buprenorphine) is excreted into breast milk in low concentrations; estimated infant dose 0.2-1.0% of maternal weight-adjusted dose. M/P ratio approximately 0.8-2.6. Breastfeeding is generally considered acceptable in mothers stable on maintenance therapy, with monitoring for infant sedation and feeding difficulties. |
| Teratogenic Risk | First trimester: Based on animal studies and limited human data, potential for fetal harm including skeletal and visceral malformations cannot be excluded. Second and third trimesters: Risk of opioid-induced neonatal abstinence syndrome (NAS) and preterm labor with chronic use. Avoid use unless benefits outweigh risks. |
■ FDA Black Box Warning
Serious infections: Increased risk of serious bacterial, mycobacterial, fungal, viral, and other opportunistic infections, including tuberculosis, leading to hospitalization or death.
| Serious Effects |
["Hypersensitivity to ruxolitinib or any component of the formulation","Severe hepatic impairment (Child-Pugh Class C)"]
| Precautions | ["Risk of serious infections (including tuberculosis, invasive fungal infections, and reactivation of hepatitis B)","Increased risk of thrombosis (including DVT, PE, and arterial thrombosis)","Elevations in liver enzymes and bilirubin","Increases in creatinine and lipid parameters (total cholesterol, LDL, HDL, triglycerides)","Possible immunosuppression and increased risk of malignancy (including lymphoma and non-melanoma skin cancer)","Withdrawal effects: abrupt discontinuation may result in worsening of symptoms (e.g., fever, respiratory distress, hypotension)"] |
Loading safety data…
| Fetal Monitoring | Maternal: Vital signs, respiratory rate, sedation level, signs of withdrawal or overdose, and adherence to treatment program. Fetal: Ultrasound for growth and anatomy in second trimester; fetal non-stress test and biophysical profile in third trimester if indicated. Neonatal: Monitor for NAS using standardized scoring tools (e.g., Finnegan) for at least 72 hours after birth. |
| Fertility Effects | Opioid use may cause menstrual cycle irregularities and anovulation due to hormone disruption. In males, may reduce libido and cause erectile dysfunction. Effects are reversible upon treatment discontinuation or stabilization. |